|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM10566782X |
| 003 |
DE-627 |
| 005 |
20231222135144.0 |
| 007 |
tu |
| 008 |
231222s1999 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed24n0353.xml
|
| 035 |
|
|
|a (DE-627)NLM10566782X
|
| 035 |
|
|
|a (NLM)10637744
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Kawakita, M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Treatment of advanced testicular cancer and toxicity of chemotherapy
|
| 264 |
|
1 |
|c 1999
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 23.02.2000
|
| 500 |
|
|
|a Date Revised 08.12.2020
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a To assess the efficacy and toxicity of chemotherapy for advanced germ cell tumors, 115 patients with testicular and extragonadal germ cell tumors were reviewed. Five-year survival rates of 19 seminoma patients and 96 non-seminoma patients were 84% and 68%, respectively. According to the analysis using three sets of prognostic criteria, Indiana University Classification, International Germ Cell Consensus Classification and K Classification, the 5-year survival rate of poor-prognosis patients was 42-45%. BEP regimen (bleomycin, etoposide and cisplatin) salvaged with VIP (etoposide, ifosfamide and cisplatin) would be the standard therapy for advanced germ cell tumors since high-dose chemotherapy had no advantage on survival over the standard-dose regimen. Early serious toxicities were observed in 18 patients (15.7%), including pulmonary fibrosis, respiratory distress, and sepsis. Poor performance status and prior radiotherapy were risk factors for fatal adverse effects. In terms of late toxicites, out of 76 patients in complete remission for at least one year after cessation of chemotherapy, 31 had numbness of extremities and 29 had tinnitus. Serial semen analyses of 38 patients showed continuous azoospermia or severe oligozoospermia in 22. These data indicated that less toxic therapy was required for good-risk patients to improve the quality of life, while more intensive therapy for poor-risk patients to be cured. Several prognostic criteria should be utilized to properly distinguish good- from poor-risk patients, and decide how to treat each patient
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Bleomycin
|2 NLM
|
| 650 |
|
7 |
|a 11056-06-7
|2 NLM
|
| 650 |
|
7 |
|a Etoposide
|2 NLM
|
| 650 |
|
7 |
|a 6PLQ3CP4P3
|2 NLM
|
| 650 |
|
7 |
|a Cisplatin
|2 NLM
|
| 650 |
|
7 |
|a Q20Q21Q62J
|2 NLM
|
| 650 |
|
7 |
|a Ifosfamide
|2 NLM
|
| 650 |
|
7 |
|a UM20QQM95Y
|2 NLM
|
| 700 |
1 |
|
|a Matsuda, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Terachi, T
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yoshida, O
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 45(1999), 11 vom: 23. Nov., Seite 783-6
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:45
|g year:1999
|g number:11
|g day:23
|g month:11
|g pages:783-6
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 45
|j 1999
|e 11
|b 23
|c 11
|h 783-6
|